The hepatitis drugs global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Hepatitis Drugs Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The hepatitis drugs market size has grown steadily in recent years. It will grow from $19.34 billion in 2023 to $20.28 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to discovery of antiviral drugs targeting hepatitis viruses, advances in diagnostic technologies for hepatitis, growing awareness of the global burden of hepatitis, expansion of hepatitis vaccination programs, development of interferon-based therapies for hepatitis.
The hepatitis drugs market size is expected to see steady growth in the next few years. It will grow to $23.92 billion in 2028 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to introduction of novel direct-acting antiviral drugs, increasing prevalence of hepatitis infections, rise in government initiatives for hepatitis prevention and treatment, advances in personalized medicine approaches for hepatitis, expansion of access to hepatitis drugs in developing countries. Major trends in the forecast period include transition from interferon-based to interferon-free therapies, development of pan-genotypic antiviral drugs for hepatitis c, integration of non-invasive diagnostic methods for liver fibrosis assessment, exploration of combination therapies for hepatitis b, growing focus on the elimination of viral hepatitis as a public health threat.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report
Scope Of Hepatitis Drugs Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Market Drivers –
The increase in number of cases of different types of hepatitis is significantly driving the growth of the hepatitis drug market. Various types of hepatitis need different drugs for treatment, which increases the demand for hepatitis drugs. For instance, in June 2022, according to the World Health Organization (WHO), a Switzerland based international public health organization, 296 million people had a chronic hepatitis B infection, with an average of 1.5 million new infections every year. This increasing number of hepatitis infections will invariably increase the need for and consumption of hepatitis drugs. Thus, the increasing number of different types of hepatitis is expected to propel the growth of hepatitis drugs in the forecast period.
Market Trends –
Product innovations have emerged as the key trend gaining popularity in the 5G chipset market. The major players in the market are developing innovative products for market growth. For instance, in June 2021, Samsung Electronics, a South Korea-based electronics company, developed 3GPP Rel.16 compliant chipsets, a range of next-generation 5G chipsets that deliver cutting-edge 5G technologies. The new chipsets consist of a second-generation 5G modem System-on-Chip (SoC), a third-generation mmWave Radio Frequency Integrated Circuit (RFIC) chip, and a Digital Front End (DFE)-RFIC integrated chip. These are designed to increase power efficiency, boost performance, and reduce the size of 5G solutions.
The hepatitis drugs market covered in this report is segmented –
1) By Drug Class: Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents
2) By Route Of Administration: Oral, Injection
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E
Get an inside scoop of the hepatitis drugs market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=6889&type=smp
Regional Insights –
North America was the largest region in the hepatitis drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Key Companies –
Major companies operating in the hepatitis drugs market report are Gilead Sciences Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Abbott Laboratories, AbbVie Inc., Arbutus Biopharma Corporation, Aspen Pharmacare Holdings Limited, Aurobindo Pharma Limited, Beijing Kawin Technology Share-Holding Co. Ltd., Beximco Pharmaceuticals Ltd., Biocon Limited, Bristol-Myers Squibb Company, Cadila Healthcare Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Enanta Pharmaceuticals Inc., Hetero Drugs Limited, Laurus Labs Limited, Lupin Pharmaceuticals Inc., Micro Labs Limited, Mylan N. V., Natco Pharma Limited, Novartis International AG, Roche Holding AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Vir Biotechnology Inc., Agenus Inc., Genentech Inc., Eisai Pharmaceuticals India Pvt. Ltd.
Table of Contents
1. Executive Summary
2. Hepatitis Drugs Market Report Characteristics
3. Hepatitis Drugs Market Trends And Strategies
4. Hepatitis Drugs Market – Macro Economic Scenario
5. Global Hepatitis Drugs Market Size And Growth
.
.
.
31. Global Hepatitis Drugs Market Competitive Benchmarking
32. Global Hepatitis Drugs Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Hepatitis Drugs Market
34. Hepatitis Drugs Market Future Outlook and Potential Analysis
35. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
